Risk of hematologic relapse among patients on the higher-risk arm, based on GSTM1 genotype, by multivariate analysis
Feature* . | Coefficient . | SE . | Hazard ratio (95% CI) . | P† . |
|---|---|---|---|---|
| GSTM1 (nonnull vs null) | 2.90 | 0.784 | 18.1 (3.9-84.3) | .0002 |
| Leukocyte count (fewer than 100 × 109/L vs at least 100 × 109/L) | -1.74 | 0.844 | 0.18 (0.03-0.92) | .04 |
| t(9;22)/BCR-ABL (present vs absent) | 0.83 | 0.949 | 2.29 (0.36-14.7) | .38 |
| t(4;11)/MLL-AF4 (present vs absent) | 2.94 | 0.972 | 19.0 (2.82-128) | .0025 |
| Day 19 marrow (at least 5% blasts vs less than 5% blasts) | -0.46 | 0.888 | 0.63 (0.11-3.58) | .60 |
| Minimal residual disease on remission date (at least 0.01% vs less than 0.01%) | 2.69 | 0.972 | 14.7 (2.18-98.5) | .0057 |
Feature* . | Coefficient . | SE . | Hazard ratio (95% CI) . | P† . |
|---|---|---|---|---|
| GSTM1 (nonnull vs null) | 2.90 | 0.784 | 18.1 (3.9-84.3) | .0002 |
| Leukocyte count (fewer than 100 × 109/L vs at least 100 × 109/L) | -1.74 | 0.844 | 0.18 (0.03-0.92) | .04 |
| t(9;22)/BCR-ABL (present vs absent) | 0.83 | 0.949 | 2.29 (0.36-14.7) | .38 |
| t(4;11)/MLL-AF4 (present vs absent) | 2.94 | 0.972 | 19.0 (2.82-128) | .0025 |
| Day 19 marrow (at least 5% blasts vs less than 5% blasts) | -0.46 | 0.888 | 0.63 (0.11-3.58) | .60 |
| Minimal residual disease on remission date (at least 0.01% vs less than 0.01%) | 2.69 | 0.972 | 14.7 (2.18-98.5) | .0057 |
This analysis was performed in the 64 patients with all features evaluable; because all patients in the higher-risk group who relapsed had an unfavorable DNA index, it was not included as a potential predictive feature.
SE indicates standard error for the coefficient estimate; CI, confidence interval.
Hazard of relapse for the first feature compared with those with the second feature.
P value was determined by Fine and Gray estimator.